Prestige Consumer Healthcare Inc. (NYSE:PBH) Receives Average Rating of “Moderate Buy” from Brokerages

Shares of Prestige Consumer Healthcare Inc. (NYSE:PBH) have been given a consensus rating of “Moderate Buy” by the five ratings firms that are presently covering the firm, Marketbeat.com reports. Two investment analysts have rated the stock with a hold rating and three have assigned a buy rating to the company. The average 12-month price target among analysts that have issued a report on the stock in the last year is $94.20.

PBH has been the subject of several recent analyst reports. DA Davidson upped their price objective on shares of Prestige Consumer Healthcare from $93.00 to $95.00 and gave the company a “buy” rating in a research note on Wednesday, August 28th. Jefferies Financial Group reaffirmed a “hold” rating and set a $76.00 price objective (up from $70.00) on shares of Prestige Consumer Healthcare in a research note on Tuesday, September 24th.

Prestige Consumer Healthcare Stock Performance

Prestige Consumer Healthcare stock opened at $77.44 on Thursday. The company has a quick ratio of 1.90, a current ratio of 3.23 and a debt-to-equity ratio of 0.65. The company has a market capitalization of $3.84 billion, a PE ratio of 18.93, a P/E/G ratio of 2.08 and a beta of 0.47. The firm has a fifty day simple moving average of $72.31 and a two-hundred day simple moving average of $69.71. Prestige Consumer Healthcare has a twelve month low of $56.61 and a twelve month high of $79.25.

Prestige Consumer Healthcare (NYSE:PBH) last posted its quarterly earnings results on Thursday, August 8th. The company reported $0.90 earnings per share for the quarter, topping the consensus estimate of $0.86 by $0.04. The business had revenue of $267.10 million during the quarter, compared to the consensus estimate of $260.54 million. Prestige Consumer Healthcare had a net margin of 18.43% and a return on equity of 12.55%. The firm’s revenue for the quarter was down 4.4% on a year-over-year basis. During the same period in the previous year, the firm posted $1.06 earnings per share. Research analysts expect that Prestige Consumer Healthcare will post 4.43 EPS for the current year.

Hedge Funds Weigh In On Prestige Consumer Healthcare

Hedge funds and other institutional investors have recently modified their holdings of the stock. State Board of Administration of Florida Retirement System increased its position in shares of Prestige Consumer Healthcare by 77.4% during the first quarter. State Board of Administration of Florida Retirement System now owns 25,221 shares of the company’s stock valued at $1,830,000 after buying an additional 11,000 shares during the period. BNP Paribas Financial Markets increased its position in shares of Prestige Consumer Healthcare by 143.4% during the first quarter. BNP Paribas Financial Markets now owns 51,246 shares of the company’s stock valued at $3,718,000 after buying an additional 30,191 shares during the period. Lombard Odier Asset Management USA Corp purchased a new position in shares of Prestige Consumer Healthcare during the second quarter valued at about $550,000. CANADA LIFE ASSURANCE Co increased its position in shares of Prestige Consumer Healthcare by 19.4% during the first quarter. CANADA LIFE ASSURANCE Co now owns 47,575 shares of the company’s stock valued at $3,453,000 after buying an additional 7,715 shares during the period. Finally, Sequoia Financial Advisors LLC grew its holdings in Prestige Consumer Healthcare by 12.9% in the third quarter. Sequoia Financial Advisors LLC now owns 9,824 shares of the company’s stock worth $708,000 after purchasing an additional 1,120 shares during the period. Hedge funds and other institutional investors own 99.95% of the company’s stock.

Prestige Consumer Healthcare Company Profile

Prestige Consumer Healthcare Inc, together with its subsidiaries, develops, manufactures, markets, distributes, and sells over-the-counter (OTC) health and personal care products in the United States and internationally. The company operates in two segments, North American OTC Healthcare and International OTC Healthcare.